Twelve-month outcomes of a community-based, father-daughter physical activity program delivered by trained facilitators.

Background: Dads and Daughters Exercising and Empowered (DADEE) is a program targeting fathers/father-figures to improve their daughters' physical activity and well-being. Previous randomised controlled efficacy and effectiveness trials of DADEE demonstrated meaningful improvements in a range of holistic outcomes for both fathers and daughters in the short-term. This study aims to assess the long-term impact (12-months) of the program when delivered in the community by trained facilitators.

Replicability, adaptability and long-term impact of the 'Healthy Youngsters, Healthy Dads' program in Newcastle, Australia.

'Healthy Youngsters, Healthy Dads' (HYHD) targets fathers to improve the health of their preschool-aged children. In a previous randomized trial, fathers and children experienced meaningful improvements in physical activity and eating behaviours. The next phase is to test the replicability and adaptability of HYHD when delivered in the community by trained facilitators.

Histological Analysis of the Effect of ATX-101 (Deoxycholic Acid Injection) on Subcutaneous Fat: Results From a Phase 1 Open-Label Study.

Background: ATX-101 is approved for submental fat reduction.

Objective: To characterize the histological effect of ATX-101 injection into subcutaneous fat.

Methods: This Phase 1 open-label study enrolled 14 adults to receive injections of ATX-101 into abdominal fat at varying concentrations (0.

ATX-101 for reduction of submental fat: A phase III randomized controlled trial.

Background: ATX-101, an injectable form of deoxycholic acid, causes adipocytolysis when injected subcutaneously into fat.

Objective: We sought to evaluate the efficacy and safety of ATX-101.

Methods: In this phase III trial (REFINE-2), adults dissatisfied with their moderate or severe submental fat (SMF) were randomized to ATX-101 or placebo.

REFINE-1, a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial With ATX-101, an Injectable Drug for Submental Fat Reduction.

Background: ATX-101, an injectable form of deoxycholic acid, is approved in the United States and Canada for submental fat (SMF) reduction.

Objective: To report results of REFINE-1, a randomized, double-blind, placebo-controlled, Phase 3 trial investigating the efficacy and safety of ATX-101.

Methods: Subjects dissatisfied with their moderate or severe SMF received ATX-101 (2 mg/cm) or placebo.

Through the Looking Glass: Exploring How College Students' Perceptions of the Police Influence Sexual Assault Victimization Reporting.

Despite increased attention, education, and prevention programs, sexual assault of college students and underreporting of this victimization remain a pervasive problem. Previous research has examined factors influencing the reporting of crimes by the public to the police, the extent of sexual victimization on college campuses, sexual assault victimization reporting and/or disclosure (for both university victims and non-university victims), and perceptions of police by university students. However, there remains a dearth of research examining whether students' perceptions of police influence their decision to report victimization, in particular sexual assault victimization.

Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeys.

Background: ST-246® is an antiviral, orally bioavailable small molecule in clinical development for treatment of orthopoxvirus infections. An intravenous (i.v.

Bone grafting in arthroscopy and sports medicine.

Bone graft substitutes include autografts, allografts, xenografts, and synthetics. Although autograft is still the gold standard, limited supply and donor morbidity must be considered. Allograft can vary in its bone-inductive qualities and may be processed into various shapes and constructs.

Disposition of Misoprostol and Its Active Metabolite in Impaired Hepatic Function.

The pharmacokinetics of misoprostol and its active metabolite, misoprostol acid, was assessed in 17 healthy subjects and 17 subjects with various degrees of hepatic impairment. Before misoprostol administration, subjects underwent antipyrine and indocyanine green clearance studies to assess hepatic functional capacity. Subjects were administered 400 mcg of oral misoprostol in an open-label design.